INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-67618-05
Application Number	10/563,682
Filing Date	January 6, 2006
First Named Inventor	Gladwin
Art Unit	1616
Examiner Name	

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
	1	5,485,827	1/23/1996	Zapol et al.
	2	5,873,359	2/23/1999	Zapol et al.
	3	5,994,444	11/30/1999	Trescony et al.
	4	6,187,744	2/13/2001	Rooney
	5	6,197,745	3/6/2001	Stamler
	6	6,291,424	9/18/2001	Stamler et al.
	7	6,358,536	3/19/2002	Thomas
	8	6,583,113	6/24/2003	Stamler et al.
	9	6,627,738	9/30/2003	Stamler et al.
	10	6,642,438	11/4/2003	Clendennen et al.
	11	6,796,966	9/28/2004	Thomas
	12	6,884,773	4/26/2005	Stamler et al.
	13	6,945,247	9/20/2005	Stamler et al.
	14	7,025,869	4/11/2006	Fine et al.
	15	7,033,999	4/25/2006	Stamler <i>et al</i> .
	16	7,202,340	4/10/2007	Stamler <i>et al</i> .
	17	US2001/0034323	10/25/2001	Rooney

EXAMINER /Ernst Arnold/ SIGNATURE:	DATE CONSIDERED:	04/16/2008
---------------------------------------	---------------------	------------

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-67618-05
Application Number	10/563,682
Filing Date	January 6, 2006
First Named Inventor	Gladwin
Art Unit	1616
Examiner Name	

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
	18	US2002/0037839	3/28/2002	Stamler et al.
	19	US2002/0095108	7/18/2002	Tsuchida et al.
	20	US2003/0022267	1/30/2003	Stamler et al.
	21	US2005/0227912	10/13/2005	Fronticelli et al.
	22	US2006/0088583	4/27/2006	Takeoka <i>et al</i> .
	23	US2006/0242671	11/9/2006	Stamler et al.
	24	US2007/0167352	7/19/2007	Winslow et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
	25	WO	96/30006	10/3/1996	Brigham and Women's
					Hospital
	26	WO	97/10265	3/20/1997	Duke University
	27	WO	03/102575	12/11/2003	Duke University
	28	WO	2004/054433	7/1/2004	Duke University
	29	WO	2006/113540	10/26/2006	Duke University
	30	WO	2006/096774	9/14/2006	Sangart, Inc.

EXAMINER /Ernst Arnold/ SIGNATURE:	DATE 04/16/2008 CONSIDERED:
---------------------------------------	-----------------------------

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-67618-05
Application Number	10/563,682
Filing Date	January 6, 2006
First Named Inventor	Gladwin
Art Unit	1616
Examiner Name	

Examiner's Initials*	Cite No. (optional)		
	31	ALI et al. "A Method to Attenuate Pneumoperitoneum-Induced Reductions in Splanchnic Blood Flow," Annals of Surgery 241 (2): 256-261 (2005)	
	32	ANGELO <i>et al.</i> "An S-nitrosothiol (SNO) synthase function of hemoglobin that utilizes nitrite as a substrate," <i>Proc. Natl. Acad. Sci. USA</i> 103 (33): 8366-8371 (2006)	
	33	BASIREDDY <i>et al.</i> "Effects of sodium nitrite on ischemia=reperfusion injury in the rat kidney" <i>Am J Physiol Renal Physiol</i> 290: 779-786 (2005)	
	34	CRAWFORD <i>et al.</i> "Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation," <i>Blood</i> 107 (2): 566-574 (2006)	
	35	DURANSKI <i>et al.</i> "Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver," <i>Journal of Clinical Investigation</i> 115 (5): 1232-1240 (2005)	
	36	GLADWIN, "Nitrite as an intrinsic signaling molecule," <i>Nature Chemical Biology</i> 1: 245-246 (2005)	
	37	GLADWIN <i>et al.</i> "Corrigendum: The emerging biology of the nitrite anion," <i>Nature Chemical Biology</i> 2: 110 (2006)	
	38	GOW et al. "The oxyhemoglobin reaction of nitric oxide," Proc. Natl. Acad. Sci. USA 96: 9027-9032 (1999)	
	39	GOW and STAMLER, "Reactions between nitric oxide and haemoglobin under physiological conditions," <i>Nature</i> 391: 169-173 (1998) (Abstract Only)	
	40	KIM-SHAPIRO <i>et al.</i> "Unraveling the Reaction of Nitric Oxide, Nitrite, and Hemoglobin in Physiology and Therapeutics," <i>Areterioscler. Thromb. Vasc. Biol.</i> 26: 697-705 (2006)	
	41	LUCHSINGER <i>et al.</i> "Routes to <i>S</i> -nitroso-hemoglobin formation with heme redox and preferential reactivity in the subunits," <i>Proc. Natl. Acad. Sci. USA</i> 100 (2): 461-466 (2003)	
	42	MCMAHON <i>et al.</i> "A nitric oxide processing defect of red blood cells created by hypoxia: Deficiency of S-nitrosohemoglobin in pulmonary hypertension," <i>Proc. Natl. Acad. Sci. USA</i> 102 (41): 14801-14806 (2005)	
	43	SHIVA <i>et al.</i> "Ceruloplasmin is a NO oxidase and nitrite synthase that determines endocrine NO homeostasis," <i>Nature Chemical Biology</i> 2: 486-493 (2006)	
	44	WINSLOW, "Red Cell Substitutes," Seminars in Hematology 44:51-59 (2007)	

EXAMINER /Ernst Arnold/ SIGNATURE:	DATE 04/16/2008 CONSIDERED:
------------------------------------	--------------------------------

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.